Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
E-Power Resources Inc. Announces Flow-Through and Hard Dollar Private Placements to Fund Summer Work Program
Juggernaut Exploration: Advancing High-grade Precious Metals Assets in Northern BC’s Golden Triangle
New INNspired Article Spotlights Rare Earth Recycling as a Strategic Investment Opportunity in U.S. Critical Mineral Supply Chain
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
